Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 14, 2020 11:21 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Closing of Public Offering of Common Stock

BEDMINSTER, N.J., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today...
January 10, 2020 08:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Pricing of Public Offering of Common Stock

BEDMINSTER, N.J., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today...
January 09, 2020 16:05 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Proposed Public Offering of Common Stock

BEDMINSTER, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today...
December 12, 2019 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Feasibility Evaluation with Third Large Biopharmaceutical Company for the Formulation of Compounds Utilizing LNC Delivery Platform

BEDMINSTER, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has entered into a feasibility evaluation with Genentech, a member of...
November 18, 2019 07:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

BEDMINSTER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief...
November 13, 2019 06:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update

– Initiated pre-screening of patients for Phase 2 ENHANCE-IT study of MAT9001 against Vascepa®. Enrollment to commence Q1 2020, with topline data expected H2 2020 – – NIH-funded Phase 2 EnACT trial of...
November 06, 2019 07:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2019 Operational and Financial Results on November 13, 2019

BEDMINSTER, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a...
October 14, 2019 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Initiates EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Fungal Cryptococcal Meningitis

BEDMINSTER, N.J., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has initiated its Phase 2...
October 07, 2019 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Receives Orphan Drug Designation From U.S. FDA for MAT2203 for the Treatment of Cryptococcosis

BEDMINSTER, N.J., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug...
September 27, 2019 08:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the 2019 Cantor Global Healthcare Conference

BEDMINSTER, N.J., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief...